Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of L-carnitine in treatment of non-alcoholic fatty liver
IRCT20240828062893N1Phase 2Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of levocarnitine in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Hamadan University of Medical Sciences. Started Jan 2025; status: completed.
02
Drugs
levocarnitine
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT20240828062893N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240828062893N1.